BioCryst Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $89.7M | $104.7M | $110.6M | $304.8M | $504.4M | $272.1M | $114.2M | $26.7M |
| Accounts Receivable | $106.8M | $79.1M | $57.0M | $50.6M | $29.4M | $8.6M | $22.1M | $4.3M |
| Inventory | $5.4M | $8.1M | $28.7M | $27.5M | $15.8M | $7.0M | $0 | $1.6M |
| Total Current Assets | $404.3M | $422.0M | $496.0M | $516.5M | $566.1M | $323.8M | $164.3M | $114.4M |
| Property, Plant & Equipment | $8.8M | $7.8M | $7.9M | $8.6M | $8.7M | $7.1M | $7.3M | $9.1M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M | $334.7M | $175.3M | $146.8M |
| Liabilities | ||||||||
| Accounts Payable | $15.8M | $11.6M | $20.9M | $14.4M | $27.8M | $18.7M | $14.0M | $7.8M |
| Total Current Liabilities | $196.1M | $160.4M | $150.0M | $105.5M | $103.7M | $105.7M | $92.3M | $69.5M |
| Long-Term Debt | $0 | $314.9M | $303.2M | $231.6M | $136.1M | $119.7M | $0 | $30.0M |
| Total Liabilities | $633.3M | $966.4M | $972.5M | $844.6M | $695.1M | $354.0M | $137.0M | $97.6M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-840.6M | $-732.0M |
| Total Stockholders' Equity | $-119.2M | $-475.9M | $-455.5M | $-294.6M | $-107.0M | $-19.3M | $38.3M | $49.2M |